HeimSHTDY • OTCMKTS
add
Sinopharm Group ADR
Við síðustu lokun
13,21 $
Dagbil
13,01 $ - 13,04 $
Árabil
10,84 $ - 14,87 $
Markaðsvirði
63,41 ma. HKD
Meðalmagn
64,55 þ.
V/H-hlutf.
-
A/V-hlutfall
-
Viðskiptafréttir
Fjármál
Rekstrarreikningur
Tekjur
Nettótekjur
| (CNY) | des. 2025info | Breyting á/á |
|---|---|---|
Tekjur | 143,69 ma. | 1,13% |
Rekstrarkostnaður | 5,00 ma. | -10,42% |
Nettótekjur | 1,85 ma. | 4,36% |
Hagnaðarhlutfall | 1,29 | 3,20% |
Hagnaður á hvern hlut | — | — |
EBITDA | 5,97 ma. | -2,51% |
Virkt skatthlutfall | 30,30% | — |
Efnahagsreikningur
Heildareignir
Heildarskuldir
| (CNY) | des. 2025info | Breyting á/á |
|---|---|---|
Reiðufé og skammtímafjárfestingar | 48,80 ma. | -10,16% |
Heildareignir | 390,36 ma. | -0,63% |
Heildarskuldir | 256,20 ma. | -3,74% |
Eigið fé alls | 134,16 ma. | — |
Útistandandi hlutabréf | 3,12 ma. | — |
Eiginfjárgengi | 0,49 | — |
Arðsemi eigna | 3,34% | — |
Ávöxtun eigin fjár | 6,42% | — |
Peningaflæði
Breyting á handbæru fé
| (CNY) | des. 2025info | Breyting á/á |
|---|---|---|
Nettótekjur | 1,85 ma. | 4,36% |
Handbært fé frá rekstri | 53,22 ma. | -10,21% |
Reiðufé frá fjárfestingum | -1,21 ma. | 67,09% |
Reiðufé frá fjármögnun | -30,23 ma. | 18,95% |
Breyting á handbæru fé | 21,77 ma. | 19,12% |
Frjálst peningaflæði | 24,05 ma. | — |
Um
Sinopharm Group Co., Ltd. is a Chinese pharmaceutical company. The parent company of Sinopharm Group was Sinopharm Industrial Investment, a 51–49 joint venture of state-owned enterprise China National Pharmaceutical Group and civilian-run enterprise Fosun Pharmaceutical.
Its H shares were listed on the Hong Kong Stock Exchange in 2009, with its IPO price of HK$16 per share. Sinopharm Group's subsidiary Sinopharm CNMC and Sinopharm Accord served as the A share counterpart of the company. However, the A share of Sinopharm Group itself was unlisted.
Sinopharm Group was ranked 829th in 2016 Forbes Global 2000 list. Wikipedia
Stofnsett
2003
Vefsvæði
Starfsfólk
94.910
